Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | MIF | P14174 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12792919 | 0.74 | TSHR (0.31) | TSHR | |
| SCHEMBL13551493 | 0.74 | CA2 (0.33) | CA2ALDH1A1TSHRTDP1ALOX15 | |
| SCHEMBL12826811 | 0.73 | CA2 (0.30) | CA2 | |
| SCHEMBL21719186 | 0.72 | AHR (0.32) | — | |
| SCHEMBL21719191 | 0.72 | — | — | |
| SCHEMBL24373233 | 0.72 | MEN1 (0.31) | ALDH1A1MAPT | |
| SCHEMBL21719393 | 0.72 | GPR84 (0.33) | — | |
| SCHEMBL21719622 | 0.72 | CA2 (0.32) | CA2ALDH1A1TSHRTDP1 | |
| SCHEMBL21737053 | 0.72 | CA2 (0.32) | CA2ALDH1A1TSHRTDP1 | |
| SCHEMBL21719433 | 0.72 | CA2 (0.32) | CA2ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240228487-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240228487-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| WO-2023210741-A1 | BENZOTRIAZOLE COMPOUND | 第一三共株式会社 | 2023-11-02 | — | — | WO | disclosed |
| US-20230331710-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO. LTD (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331710-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO. LTD (CN) | 2023-10-19 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070082892-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| US-20070066819-A1 | PROCESS FOR THE PREPARATION OF BENZOTRIAZEPINE DERIVATIVES | JANSSEN PHARMACUETICA N.V., (BE) | 2007-03-22 | — | — | US | disclosed |
| CN-1238362-C | 'Pi' complex compounds | BAYER AG (DE) | 2006-01-25 | — | — | CN | disclosed |
| US-6433112-B1 | COORDINATION POLYMERIZATION CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-13 | — | — | US | disclosed |
| EP-1042336-B1 | PI-COMPLEX COMPOUNDS | BAYER AG (DE) | 2002-04-03 | — | — | EP | disclosed |
| CN-1284960-A | Pi complex compound | BAYER AG (DE) | 2001-02-21 | — | — | CN | disclosed |
| EP-1042336-A1 | PI-COMPLEX COMPOUNDS | Bayer Aktiengesellschaft (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033852-A1 | π-COMPLEX COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-08 | — | — | WO | disclosed |
| CN-1145370-A | Olefin polymerization catalyst and process for producing polyolefin using the same | SUMITOMO CHEMICAL CO (JP) | 1997-03-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331710-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREOF | C9, CFB, C5 | CA2 4669/4885ALDH1A1 3003/4885TSHR 3331/4885 |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | BCKDK, CYP11B2, HSD17B7 | CA2 2818/4885ALDH1A1 348/4885TSHR 3205/4885 |
| US-20070066819-A1 | PROCESS FOR THE PREPARATION OF BENZOTRIAZEPINE DERIVATIVES | CCKBR, CCKAR, GRPR | CA2 1238/4885ALDH1A1 3751/4885TSHR 164/4885 |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | CA2 2103/4885ALDH1A1 1532/4885TSHR 4825/4885 |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | CA2 3572/4885ALDH1A1 1674/4885TSHR 2165/4885 |
| US-20070082892-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | CA2 2088/4885ALDH1A1 2440/4885TSHR 287/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | CA2 4709/4885ALDH1A1 1427/4885TSHR 3370/4885 |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | CA2 2088/4885ALDH1A1 2440/4885TSHR 287/4885 |
| US-20240228487-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND APPLICATION THEREOF | TRPM2, TRPM8, TRPM7 | CA2 86/4885ALDH1A1 2555/4885TSHR 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.